Please see new guidance from the UK Chemotherapy Board on ‘Personalised Medicine Approach For Fluoropyrimidine-based Therapies’.
Objective of document: To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
Full guidance can be accessed HERE or found in our resource center in the BOPA website.
Join the International Society of Oncology Pharmacy Practitioners and the Canadian Association of Pharmacy Oncology for leading edge education to advance your oncology pharmacy practice and knowledge! The ISOPP CAPhO Symposium 2025 will take…
Announcement: New Specialist pancreatic cancer E-Learning Resource Now Available We’re excited to announce that a new specialist e-learning resource has been added to our website! This invaluable resource, provided by…
The recordings of the UK BMT Pharmacists Group Educational Meeting June 2024 is now available to watch via this link: UK BMT Pharmacists Group Educational Meeting Series (June 2024) …
National survey about the implementation of JBDS/UK chemo board guidelines on the management of glycaemia in people with cancer. The purpose is to understand some of the enablers and barriers…
The 28th BOPA Annual Conference in 2025 will be held at the ICC Belfast on 3-5 October 2025.
Check out the latest information here: Latest Conference 2025 – BOPA
Everything you need to know
